Drug Channels delivers timely analysis and provocative opinions on pharmaceutical economics and the drug distribution system. It is written by Adam J. Fein, Ph.D., one of the country's foremost experts on pharmaceutical economics and channel strategy. Drug Channels reaches an engaged, loyal and growing audience of more than 24,000 subscribers. Learn more...

Friday, May 17, 2019

A New Starting Point for Patient Support: Technology-Driven Hub Services

Today’s guest post comes from Erica Conroy, VP of Specialty at CoverMyMeds and Bill Nolan, VP/GM of Access and Adherence at RxCrossroads by McKesson.

Erica and Bill discuss the challenges that specialty pharmacy patients encounter when accessing and utilizing hub services. They also present evidence showing that how hub services positively affect patient outcomes.

To learn more, download CoverMyMeds’ whitepaper: Revolutionizing Patient Access and Support for Specialty Therapies: Multiple Sclerosis.

Read on for their insights.

Thursday, May 16, 2019

340B Health Gets It Wrong … Again

This week, Drug Channels published our annual update on the growth of the 340B Drug Pricing Program. See 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines.

Right on cue, 340B Health, which lobbies for hospitals that participate in the 340B program, immediately issued its annual rebuttal of the Health Resources and Services Administration (HRSA) data that we used.

340B Health was particularly distressed that our analyses “focused on 340B sales instead of discounts.” Below, you will see that when the program is measured using 340B Health’s suggested approach, it accounted for 9% to 11% of the relevant market in 2018. That’s even higher than my computation, which showed that the 340B program constituted 7% to 8% of the total drug market that year.

We’re all entitled to our own opinions about the 340B program, but we’re not entitled to our own facts. It is indisputable that 340B contributes to a large and growing share of the market.

Tuesday, May 14, 2019

EXCLUSIVE: 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines

The 340B Drug Pricing Program continues to expand at double-digit rates. According to our government contacts, discounted 340B purchases hit a record $24.3 billion in 2018. That figure is an astonishing 26% higher than its 2017 counterpart.

What’s more, we have found that since 2014, purchases under the program have grown at an average rate of 28% per year. By comparison, manufacturers’ net drug revenues have grown at an average rate of below 5% over the same period. Consequently, the 340B program has grown to account for at least 7% to 8% of the total U.S. drug market.

Nearly all of the billions in 340B discounts have accrued to hospitals. Yet hospitals' charity care has dropped amid the 340B program’s growth. The charts have the details.

So where did the money go? We have no idea, because hospitals and their lobbyists fight any call for them to disclose or account for how they use their 340B profits—while consistently misrepresenting the program's size and growth. Be skeptical when you read random stories about the generosity of a 340B covered entity. As always, the plural of anecdote is not data.

Read on for the latest details and ponder who really benefits from the 340B program's size—and how much longer this shocking growth can continue.

Monday, May 13, 2019

CBI’s Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers

CBI’s Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers
June 19-20, 2019 | Alexandria, VA
www.cbinet.com/Medicare

CBI’s Strategic Medicare Contracting Forum for Bio/Pharma Manufacturers provides a real-time analysis of newly proposed regulations, including the proposal to eliminate rebates, the use of step therapy under Medicare Part B, changes to coverage gap, influence of the International Pricing Index and much more.

Exclusive Offer for Drug Channels Readers:
Register Now and SAVE $400* using promo code MED400.

Taking place June 19-20 in Alexandria, VA, we invite you to convene with fellow stakeholders to receive an in-depth look into legislative and regulatory changes to Medicare and how it will impact manufacturers. You and your team members will benefit from this opportunity by gaining insights from industry experts on the complex changes occurring within Medicare, walking away with critical perspectives and robust knowledge on key topics.

Hear from 20+ Key Experts on High-Impact Issues, including:
  • [Keynote Address] Washington Update on Medicare Policy — The White House
  • HHS Keynote Address — U.S. Department of Health and Human Services (invited)
  • International Pricing Index Model: Evaluate the Proposed Changes for Medicare Part B Drugs — American Action Forum and Pacific Research
  • Examine the Implementation Strategies for Step Therapy Under Medicare Part B — BIO and Bristol-Myers Squibb
  • [Panel Discussion] Discover Coverage and Payment Strategies for Novel and High Cost Therapies for Rare Diseases Under Medicare Parts A and B — Health Policy Strategies, Inc., King & Spalding and Gilead Sciences
  • Impact of Value Frameworks on Access to Medications — Pfizer Inc.
  • What’s Next for Medicare? — Perspective From Capitol Hill — U.S. House of Representatives
Visit www.cbinet.com/Medicare to view the complete speaker and in-depth session lineup, then register using promo code MED400 for this exclusive savings of $400 off!

*Discount expires 6/18/19; cannot be combined or applied to existing registration. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, May 07, 2019

The State of Specialty Pharmacy 2019: Industry Trends and Photos from #Asembia19

Last week, Paula and I had the pleasure of attending Asembia’s 2019 Specialty Pharmacy Summit at the wonderful Wynn Las Vegas.

The Specialty Pharmacy Summit remains the most important forum for learning, networking, and conducting business throughout the entire specialty marketplace.

Today marks the ninth year that I will violate Vegas code and tell you what happened there.

Below, I offer reflections on the meeting, share my experiences during the featured session, and highlight four crucial specialty industry trends. You’ll also find a link to the conference’s Featured Session slides and cool photos—including two of the many selfies for which I posed during the meeting. Enjoy!

Monday, May 06, 2019

Patient Support Services Congress


Patient Support Services Congress
June 19-20, 2019 | Sheraton University City | Philadelphia, PA
www.cbinet.com/PatientServices

Join your colleagues for CBI’s Patient Support Services Congress — an industry-driven meeting, where you can participate in a wide-ranging dialogue surrounding customized patient support, operational efficiencies and compliant program services.

Visit www.cbinet.com/PatientServices for more information. Drug Channels subscribers will save $250 off the standard registration rate when they use discount code DRC250* by March 1, 2019.


A DIALOGUE-DRIVEN MEETING FOR ENFORCEMENT TRENDS AND NEXT-GENERATION APPROACHES TO PATIENT SERVICES:
  • Examine the regulatory implications around copy cards and foundation relationships
  • Discuss challenges in providing compliant assistance to functionally uninsured patients under Medicare Part D
  • Assess the pros and cons of different support service models
  • Learn how hubs qualify patients based on reimbursement, insurance, and industry knowledge
  • Explore how manufacturers can tailor patient support services to individual facilities without losing the integrity of the program’s guidelines
  • Address in-house versus outsourced hub services and the role that compliance plays in those decisions
  • Review training and monitoring procedures for your field nurses to alleviate risk as operations scale up
ENHANCE YOUR LEARNING EXPERIENCE

Nurse Educator Programs takes place one day prior, on June 18th. Join your Compliance, Patient Access, and Medical Affairs counterparts to uncover leading strategies to ensure compliance throughout the design and management of Nurse Educator Programs.

Visit www.cbinet.com/PatientServices for more information. Drug Channels subscribers will save $250 off the standard registration rate when they use discount code DRC250* by March 1, 2019.


*Offer applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, May 03, 2019

Specialty Pharmacy M&A: Our Look at 2018’s Deals (rerun)

This week, I’m rerunning some popular posts while I attend Asembia’s 2019 Specialty Pharmacy Summit.

Click here to see the original post and comments from January 2019.


Let’s kick off 2019 with a quick review of last year’s specialty pharmacy mergers and acquisitions (M&A). Our list (below) includes only deals that were publicly announced in 2018.

Pharmacy benefit managers (PBMs) were especially busy. CVS Health bought five specialty pharmacies. UnitedHealth’s OptumRx bought Avella Specialty Pharmacy, the largest independent specialty pharmacy.

Diplomat Pharmacy was uncharacteristically quiet during 2018, though it had been one of the most active acquirers in previous years.

The specialty pharmacy industry is rapidly maturing, so I expect many more exits in the coming years. Looking to pick up a fast-growing specialty pharmacy? Click here for your post-holiday shopping list.

Thursday, May 02, 2019

Independent Pharmacy Economics Keep Deteriorating (rerun)

This week, I’m rerunning some popular posts while I attend Asembia’s 2019 Specialty Pharmacy Summit.

Click here to see the original post and comments from January 2019.


Time for Drug Channels’annual look at independent pharmacy owners’ business economics, drawn from the recently released 2018 National Community Pharmacists Association (NCPA) Digest, Sponsored by Cardinal Health. Here's the press release: NCPA Releases 2017 Digest.

Below, I update our estimates on pharmacy economics and margins. Our analysis reveals that independent pharmacy owners have faced another year of deteriorating finances.

What's more, we estimate that in 2017, the average pharmacy owner’s salary fell to a level comparable to that of an employed pharmacist. Owning a pharmacy, with all of its hassles and additional obligations, now brings the same reward as being an employee. I wonder how many owners will conclude that it’s barely worth the risk and effort.

Read on for our look at pharmacy profits and some comments on the industry’s competitive dynamics, including the financial impact of direct and indirect remuneration (DIR) fees.

The pharmacy consolidation endgame is getting closer. The next time you see a pharmacy owner, offer your condolences.

Wednesday, May 01, 2019

Express Scripts Launches a New Formulary for a World Without Rebates. Will Plan Sponsors and Drug Makers Play Along? (rerun)

This week, I’m rerunning some popular posts while I attend Asembia’s 2019 Specialty Pharmacy Summit.

This is an especially timely rerun. Believe it or not, Express Scripts' 2019 formulary prefers Eli Lilly's high-list/high-rebate Humalog insulin over the authorized generic version that is being sold at a 50% lower list price. The authorized generic will be preferred only on Express Scripts' Flex Formulary, which has very low adoption. 


Bottom line: Many plans still crave rebate dollars. Sorry, patients with deductibles and coinsurance. The gross-to-net bubble lives on! 

Click here to see the original post and comments from November 2018.


Express Scripts has just announced its National Preferred Flex Formulary, a new option that favors drugs with lower list prices over the high-list/high-rebate versions of these products. Click here to read the press release.

This new formulary signals that Express Scripts is trying to prepare its plan sponsor clients for a world without rebates. The formulary also provides a way for Express Scripts to prepare itself for such a world.

As I explain below, many plan sponsors embrace the warped incentives of the gross-to-net bubble—the ever-growing pile of money between a manufacturer’s list price for a drug and the net price after rebates and other reductions. I outline two crucial payer and PBM factors that make it difficult for manufacturers to cut list prices and pop the gross-to-net bubble.

Express Scripts’ new formulary challenges plan sponsors that are addicted to rebate dollars. Let’s see how many plan sponsors will prefer a low list-price over a high-list/high-rebate product—and how many more manufacturers will respond with lower list prices.

Tuesday, April 30, 2019

My Wall Street Journal Op-Ed: Don’t Blame Drug Prices on ‘Big Pharma’ (rerun)

This week, I’m rerunning some popular posts while I attend Asembia’s 2019 Specialty Pharmacy Summit.

Click here to see the original post and comments from February 2019.


Yesterday, The Wall Street Journal published my op-ed: Don’t Blame Drug Prices on ‘Big Pharma’. The article text is pasted below for those who don't subscribe.

I wrote this piece for a general business audience, though my arguments about rebates and patient out-of-pocket costs will be familiar to regular readers of Drug Channels. Alas, I had to omit such insider terms as gross-to-net bubble, direct and indirect remuneration, and SpongeBob SquarePants.

A personal note: I have been reading the WSJ daily since I was 18 years old. It’s a genuine thrill to see my byline on an op-ed in this newspaper. Another item off my bucket list!

Monday, April 29, 2019

Financial Strategies and Accounting for Bioscience Companies

Financial Strategies and Accounting for Bioscience Companies
June 11-12, 2019 | San Francisco, CA
www.cbinet.com/financialstrategies

Expectations have never been higher as more small and mid-sized life science companies prepare to launch new and innovative products in a competitive marketplace. Gross-to-Net remains a top risk, especially after a launch, and it is pivotal to achieve accuracy in GTN forecasts to avoid large adjustments.

Ensure success by gaining proven pre-revenue commercialization strategies, frameworks for managing gross-to-net estimates and mitigating risk, models to scale the business and grow a best-in-class finance function, hearing, timely updates on tax and legal matters, and industry expertise for communications and investor relations at CBI’s Financial Strategies and Accounting Summit for Bioscience Companies.

Visit www.cbinet.com/financialstrategies for further details and to register. Drug Channels readers will save $400 off the standard rate when they use discount code NHA949 and register prior to May 17th.*

Sign up for the agenda and speaker announcements here. Here’s a sneak peek into who you’ll be hearing from:
  • Alan Fuhrman, Chief Financial Officer, Amplyx Pharmaceuticals
  • Laurie Stelzer, Chief Financial Officer, Halozyme
  • Marc Belsky, Chief Financial Officer, Kezar Life Sciences
  • Robin Washington, Chief Financial Officer, Gilead Sciences
  • Mark Kaufmann, Chief Financial Officer, Ardelyx
  • Murray Kay, former Commercial Controller, Abbvie
  • Jennifer Sharpe, Executive Advisor, Life Sciences Revenue Analytics, IntegriChain
Visit www.cbinet.com/financialstrategies for further details and to register. Drug Channels readers will save $400 off the standard rate when they use discount code NHA949 and register prior to May 17th.*

CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, April 26, 2019

Help for the Patient Journey–Electronic Modernization of Medication Access

Today’s guest post comes from Ben Stormer, VP of Product Development and Strategy for Specialty at CoverMyMeds.

Ben discusses how automatic, streamlined electronic enrollment in patient hub services will improve patients' adherence to specialty medication.

To learn more, connect with CoverMyMeds at the Asembia Specialty Pharmacy Summit next week in Las Vegas.

Read on for Ben’s insights.